A first-in-human phase I study of sEphB4-HSA in patients with advanced solid tumors with expansion at the maximum tolerated dose (MTD) or recommended phase II dose (RP2D). (December 2016) - El-Khoueiry, A.; Gitlitz, B.; Cole, S.; Tsao-Wei, D.; Goldkorn, A.; Quinn, D.; Lenz, H.J.; Nieva, J.; Dorff, T.; Oswald, M.; Berg, J.; Menendez, X.; et al.